Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
empagliflozin 在治療馬來西亞慢性心衰竭及保留或輕度降低射血分數患者中的成本效益分析。
PLoS One 2024-08-23
Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
心力衰竭患者中 Empagliflozin 在保留射血分數患者中的成本效益。
Circ Cardiovasc Qual Outcomes 2022-11-08
Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
Empagliflozin在心臟收縮功能保留型心衰患者中的成本效益性。
JAMA Intern Med 2023-11-08
Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
在中國心衰患者中,empagliflozin對收縮功能降低和保留的心衰患者的成本效益分析。
Front Pharmacol 2022-11-18
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
一項歐洲跨國多中心的 empagliflozin 在收縮功能降低型心衰竭中的成本效益分析。
Eur J Health Econ 2023-10-07
Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China.
在中國治療心臟衰竭伴隨降低射出分數的 empagliflozin 的成本效益。
Front Cardiovasc Med 2022-12-06
Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore.
新加坡心衰竭患者中 Empagliflozin 輔助標準治療的成本效益。
Value Health Reg Issues 2023-03-07
Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
達帕格列酮和恩帕格列酮治療降低射出分數心衰的成本效益性。
Int J Cardiol 2023-06-27
Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
將此醫學文章的標題翻譯為繁體中文(zh-TW):「將 empagliflozin 加入標準治療方案對馬來西亞心臟衰竭患者的成本效益分析」。
Front Pharmacol 2023-07-01
Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
英格蘭心臟衰竭患者中 empagliflozin 的成本效益。
J Cardiovasc Med (Hagerstown) 2023-09-25